IDP-023 demonstrates good safety, efficacy in relapsed or refractory myeloma
In a first-in-human study, IDP-023 demonstrated a promising safety and efficacy profile in patients with relapsed or refractory multiple myeloma, according to findings
SITC 2025
Multiple Myeloma
Multiple Myeloma
News
Society Updates
Young Investigator Program
SOHO Young Investigator spotlight: Meet Maha Hameed, MD
As a resident physician who is fascinated by hematologic malignancies, Maha Hameed, MD, brings a distinctive combination of scientific intrigue and personal drive
SITC 2025
Leukemia
Acute Lymphoblastic Leukemia
News
Natural killer T-cells show promise for ‘off-the-shelf’ cancer immunotherapy for NHL, ALL
Allogeneic natural killer T cells (NKTs) expressing CD19-specific chimeric antigen receptors (CARs) are well tolerated and can mediate objective responses in non-Hodgkin’s lymphoma
Multiple Myeloma
Video Interviews
Dr. Mateos discusses blenrep/DREAMM-7 trial
Dr. Mateos was the lead investigator on the trial, which investigated belantamab mafodotin (blenrep) with bortezomib and dexamethasone (BVd) versus daratumumab with bortezomib
Leukemia
Acute Myeloid Leukemia
Novel AML product candidate granted orphan drug designation by FDA
Novel product candidate M2T-CD33 (LTI-214) was granted orphan drug designation by the US Food and Drug Administration for the treatment of acute myeloid
Leukemia News
SOHO 2025
Dr. Jabbour discusses investigational menin inhibitor bleximenib
In this interview at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at the
Leukemia News
SOHO 2025
Leukemia
Chronic Lymphocytic Leukemia
Obesity increases infection risk in CLL for patients treated with a BTKi
Patients with chronic lymphocytic leukemia (CLL) who have a body mass index (BMI) of 40 or higher (obesity class 3) are at a
Leukemia
Chronic Lymphocytic Leukemia
SOHO Insider Podcast
Drs. O’Brien, Jain discuss FLAIR trial, BTK degraders in CLL
In this episode of the SOHO Insider podcast, Susan O’Brien, MD, a professor of medicine from the Chao Family Comprehensive Cancer Center at
Leukemia
Acute Myeloid Leukemia
FDA approves revumenib in relapsed or refractory NMP1-mutated AML
The US Food and Drug Administration (FDA) has approved revumenib (Revuforj®) in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The
ESMO 2025
Acute Lymphoblastic Leukemia
Aggressive B-Cell Lymphomas
Multiple Myeloma
Myelodysplastic Syndromes
Despite digital advances, cancer research remains costly, burdensome
Clinical cancer research remains too expensive and too burdensome, even amid a proliferation of digital tools designed to improve it, according to Ines